Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$67.3 million.

  • ImmunityBio's Net Income towards Common Stockholders rose 2154.82% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 4068.11%. This contributed to the annual value of -$413.6 million for FY2024, which is 2915.24% up from last year.
  • Per ImmunityBio's latest filing, its Net Income towards Common Stockholders stood at -$67.3 million for Q3 2025, which was up 2154.82% from -$92.6 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Net Income towards Common Stockholders ranged from a high of -$59.2 million in Q4 2024 and a low of -$233.4 million during Q4 2023
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$95.6 million (2023), whereas its average is -$108.1 million.
  • As far as peak fluctuations go, ImmunityBio's Net Income towards Common Stockholders tumbled by 11547.37% in 2023, and later skyrocketed by 7464.63% in 2024.
  • ImmunityBio's Net Income towards Common Stockholders (Quarter) stood at -$91.6 million in 2021, then dropped by 18.32% to -$108.3 million in 2022, then crashed by 115.47% to -$233.4 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then dropped by 13.68% to -$67.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$67.3 million in Q3 2025, compared to -$92.6 million in Q2 2025 and -$129.7 million in Q1 2025.